当前位置:肿瘤瞭望>资讯>正文

来逛一逛2021 ASCO GU春节庙会,这些重头戏不能错过!

作者:肿瘤瞭望   日期:2021/3/15 13:47:21  浏览量:7990

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

编者按:2021年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会(ASCO GU)将于2月11-13日以虚拟会议形式举行。在为期3天的会议,适逢中国农历新年,ASCO GU 将为我们献上哪些学术大餐?本文整理大会全体报告(General Session)、口头报告(Oral Abstract Session)即将公布的重磅研究。

全体报告


Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard.

68Ga-PSMA-11 PET/CT和mpMRI对原发性前列腺癌的检出、前列腺内定位和局部扩展的头对头比较:一项以组织病理学为金标准的单中心影像学研究

作者:Ida Sonni,et al

摘要号:193

时间:2月11日 10:00pm(CST)


177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)

177Lu-PSMA-617(LuPSMA)对比卡巴他赛在多西他赛治疗后进展的转移性去势抵抗前列腺癌(mCRPC)中的治疗:包括无进展生存期(PFS)和患者报告结局(PROs)等结果更新(TheraP ANZUP 1603)

作者:Michael S. Hofman,et al

摘要号:6

时间:2月11日 11:00pm(CST)


Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)

奥拉帕利联合或不联合西地尼布治疗转移性去势抵抗前列腺癌(mCRPC)的随机Ⅱ期研究的生物标志物分析

作者:Rana R. McKay,et al

摘要号:7

时间:2月12日 03:15 am(CST)


Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.

临床晚期阴茎癌(pSCC)和男性尿道鳞状细胞癌(uSCC):一项比较基因组图谱(CGP)的研究

作者:Philippe E. Spiess, et al

摘要号:2

时间:2月12日 09:55 pm(CST)


Socio-environmental conditions associated with geospatial clusters of urothelial carcinoma: A multi-institutional analysis.

与尿路上皮癌地理空间簇相关的社会环境条件:一项多机构分析

作者:Daniel C. Edwards,et al

摘要号:392

时间:2月13日 12:30 am(CST)


First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

针对高危肌层浸润性尿路上皮癌(MIUC)患者根治性手术后纳武利尤单抗对比安慰剂辅助治疗的3期CheckMate 274试验的首次结果

作者:Dean F. Bajorin,et al

摘要号:391

时间:2月13日 04:45 am(CST)


Peri-operative morbidity and mortality in a modern series of patients treated with cytoreductive nephrectomy (CN) at five centers.

在五个中心接受减瘤性肾切除术(CN)治疗的现代系列患者的围手术期发病率和死亡率

作者:Ashanda R. Esdaille,et al

摘要号:268

时间:2月13日 11:00 pm(CST)


口头报告(前列腺癌)

时间:2月11日 01:45 am(CST)


Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC)

非转移性去势抵抗性前列腺癌(nmCRPC)中与阿帕鲁胺(APA)长期缓解相关的分子决定因素

作者:Felix Y. Feng,et al

摘要号:8


Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

ACIS最终结果:一项随机、安慰剂(PBO)对照的阿帕鲁胺+醋酸阿比特龙+泼尼松(APA+AAP)对比醋酸阿比特龙+泼尼松(AAP)治疗转移性去势抵抗前列腺癌(mCRPC)患者的双盲3期研究

作者:Dana E. Rathkopf,et al

摘要号:9


Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial

前列腺切除术后生化复发前列腺癌的剂量强化放疗与常规剂量挽救放疗:SAKK 09/10随机Ⅲ期试验的6年结果

作者:Pirus Ghadjar,et al

摘要号:194


Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy

临床细胞周期风险评分与放疗后转移的相关性以及可避免联合雄激素剥夺治疗前列腺癌患者的鉴别

作者:Jonathan D. Tward,et al

摘要号:195


口头报告(尿路上皮癌及其他)

时间:2月13日 03:15 am(CST)


Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST)

Ⅰ期精原细胞瘤睾丸癌的影像学检查方式和频率:一项随机Ⅲ期析因试验(TRISST)结果

作者:Johnathan K. Joffe,et al

摘要号:374


SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma

SEMS试验:早期转移性精原细胞瘤手术治疗的前瞻性、多中心Ⅱ期临床试验结果

作者:Siamak Daneshmand,et al

摘要号:375


Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

EV-301研究主要结果:enfortumab-vedotin对比化疗治疗局部晚期或转移性尿路上皮癌患者的Ⅲ期试验

作者:Thomas Powles,et al

摘要号:393


EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors

EV-201研究队列2:Enfortumab vedotin在既往接受PD-1/PD-L1抑制剂治疗的局部晚期或转移性尿路上皮癌不适合顺铂患者中的应用

作者:Arjun V. Balar,et al

摘要号:39


口头报告(肾细胞癌)

时间:2月14日 02:00 am(CST)


Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

仑伐替尼(LEN)联合帕博利珠单抗(PEMBRO)或依维莫司(EVE)对比舒尼替尼(SUN)作为晚期肾细胞癌(RCC)患者一线治疗的3期试验(CLEAR研究)

作者:Robert J. Motzer,et al

摘要号:269


Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

舒尼替尼对比卡博替尼、克唑替尼或沃利替尼治疗转移性乳头状肾细胞癌:来自随机Ⅲ期SWOG 1500研究的结果

作者:Sumanta K. Pal,et al

摘要号:270


The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study

晚期肾透明细胞癌(RCC)患者口服HIF-2α抑制剂MK-6482:一项Ⅰ/Ⅱ期研究的随访更新

作者:Todd M. Bauer,et al

摘要号:273


Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)

口服缺氧诱导因子2α(HIF-2α)抑制剂MK-6482联合卡博替尼治疗晚期肾透明细胞癌(ccRCC)的2期研究

作者:Toni K. Choueiri,et al

摘要号:272

版面编辑:洪山  责任编辑:卢宇

本内容仅供医学专业人士参考


泌尿

分享到: 更多

相关幻灯